NeuraStasis
Private Company
Total funding raised: $3.5M
Overview
NeuraStasis is pioneering a novel neuroprotective device, StrokeGuard, to address the critical, untreated time gap between stroke onset and hospital arrival. The company's technology employs a closed-loop, AI-driven system that non-invasively stimulates the trigeminal nerve to increase cerebral blood flow, aiming to slow neuronal death during transport. This approach is modeled on the successful deployment paradigm of cardiac AEDs, targeting placement in ambulances and public facilities. If successful, StrokeGuard could transform pre-hospital stroke care by providing the first emergency intervention to 'buy time' for patients awaiting definitive treatment.
Technology Platform
Adaptive closed-loop neuromodulation system combining near-infrared optical sensing of cerebral oxygenation, a proprietary AI algorithm, and non-invasive trigeminal nerve stimulation to increase collateral blood flow for neuroprotection.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
NeuraStasis appears to be pioneering a unique device category for pre-hospital stroke neuroprotection. Direct competitors are not evident, but the space includes pharmaceutical neuroprotectants (which have historically failed) and other neuromodulation approaches for stroke recovery (typically used in rehabilitation, not acute care). The company's main competition is the status quo: no intervention during transport.